Literature DB >> 1607253

Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. An ECOG pilot study.

R S Witte1, C Walsh, H Fisher, M M Okem, D J Reding, D L Trump.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1607253     DOI： 10.1007/bf01275482

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

1.  Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.

Authors:  C A Koller; B S Mitchell
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

2.  Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.

Authors:  N Winick; G R Buchanan; S B Murphy; A Yu; J Boyett
Journal:  Med Pediatr Oncol       Date:  1988

3.  Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.

Authors:  H G Prentice; N H Russell; N Lee; K Ganeshaguru; H Blacklock; A Piga; J F Smyth; A V Hoffbrand
Journal:  Lancet       Date:  1981-12-05       Impact factor: 79.321

4.  The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.

Authors:  M R Grever; M F Siaw; W F Jacob; J A Neidhart; J S Miser; M S Coleman; J J Hutton; S P Balcerzak
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

Review 5.  2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.

Authors:  P J O'Dwyer; B Wagner; B Leyland-Jones; R E Wittes; B D Cheson; D F Hoth
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

6.  Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).

Authors:  A S Spiers; D Moore; P A Cassileth; D P Harrington; F J Cummings; R S Neiman; J M Bennett; M J O'Connell
Journal:  N Engl J Med       Date:  1987-04-02       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.